Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions

[21] EFFECTS OF RANOLAZINE ON LEFT-VENTRICULAR REGIONAL DIASTOLIC FUNCTION IN PATIENTS WITH ISCHEMIC-HEART-DISEASE [J]. CARDIOVASCULAR DRUGS AND THERAPY, 1994, 8 (05) : 741 - 747

[22] Hoffmann Peter, 2006, Journal of Pharmacological and Toxicological Methods, V53, P87, DOI 10.1016/j.vascn.2005.07.003

[23] Effect of renal impairment on multiple-dose pharmacoldnctics of extended-release ranolazine [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (03) : 288 - 297

[24] Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (04) : 422 - 433

[25] Evidence that ranolazine behaves as a weak β1- and β2-adrenoceptor antagonist in the rat cardiovascular system [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 363 (04) : 464 - 471

[26] The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme a thiolase [J]. CIRCULATION RESEARCH, 2003, 93 (03) : E26 - E32

[27] Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1996, 81 (02) : 905 - 910

[28] MORROW DA, IN PRESS AM HEART J

[29] Murphy E, 1999, CIRC RES, V84, P1469

[30] Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (03) : 311 - 316

[21] EFFECTS OF RANOLAZINE ON LEFT-VENTRICULAR REGIONAL DIASTOLIC FUNCTION IN PATIENTS WITH ISCHEMIC-HEART-DISEASE [J]. CARDIOVASCULAR DRUGS AND THERAPY, 1994, 8 (05) : 741 - 747

[22] Hoffmann Peter, 2006, Journal of Pharmacological and Toxicological Methods, V53, P87, DOI 10.1016/j.vascn.2005.07.003

[23] Effect of renal impairment on multiple-dose pharmacoldnctics of extended-release ranolazine [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (03) : 288 - 297

[24] Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (04) : 422 - 433

[25] Evidence that ranolazine behaves as a weak β1- and β2-adrenoceptor antagonist in the rat cardiovascular system [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2001, 363 (04) : 464 - 471

[26] The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme a thiolase [J]. CIRCULATION RESEARCH, 2003, 93 (03) : E26 - E32

[27] Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle [J]. JOURNAL OF APPLIED PHYSIOLOGY, 1996, 81 (02) : 905 - 910

[28] MORROW DA, IN PRESS AM HEART J

[29] Murphy E, 1999, CIRC RES, V84, P1469

[30] Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (03) : 311 - 316